Pinnacle Associates
RARE icon

Pinnacle Associates’s Ultragenyx Pharmaceutical RARE Stock Holding History

Pinnacle Associates’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.3M Buy
152,925
+21,821
+17% +$524K 0.03% 388
2026
Q2 		$4.38M Buy
131,104
+28,394
+28% +$705K 0.05% 293
2026
Q1 		$2.15M Sell
102,710
-8,850
-8% -$199K 0.03% 383
2025
Q4 		$2.57M Sell
111,560
-3,285
-3% -$108K 0.03% 356
2025
Q3 		$3.45M Buy
114,845
+577
+0.5% +$17.3K 0.05% 304
2025
Q2 		$4.15M Sell
114,268
-29,107
-20% -$1.05M 0.06% 265
2025
Q1 		$5.19M Sell
143,375
-5,118
-3% -$213K 0.08% 233
2024
Q4 		$6.25M Buy
148,493
+29,133
+24% +$1.45M 0.08% 211
2024
Q3 		$5.71M Sell
119,360
-41,660
-26% -$2.12M 0.1% 222
2024
Q2 		$6.62M Buy
161,020
+41,633
+35% +$1.78M 0.1% 202
2024
Q1 		$5.57M Buy
119,387
+27
+0% +$1.27K 0.09% 234
2023
Q4 		$5.71M Buy
119,360
+5
+0% +$194 0.1% 225
2023
Q3 		$4.26M Sell
119,355
-3,841
-3% -$152K 0.08% 244
2023
Q2 		$5.68M Sell
123,196
-3,201
-3% -$148K 0.1% 217
2023
Q1 		$5.07M Sell
126,397
-2,039
-2% -$87.5K 0.1% 205
2022
Q4 		$5.95M Sell
128,436
-1,982
-2% -$78K 0.13% 183
2022
Q3 		$5.4M Sell
130,418
-3,640
-3% -$187K 0.12% 193
2022
Q2 		$8M Sell
134,058
-2,221
-2% -$137K 0.17% 147
2022
Q1 		$9.9M Sell
136,279
-5,295
-4% -$368K 0.18% 150
2021
Q4 		$11.9M Sell
141,574
-782
-0.5% -$63.6K 0.21% 132
2021
Q3 		$12.8M Sell
142,356
-4,159
-3% -$376K 0.24% 119
2021
Q2 		$14M Buy
146,515
+1,225
+0.8% +$128K 0.25% 115
2021
Q1 		$16.5M Sell
145,290
-13,065
-8% -$1.78M 0.32% 92
2020
Q4 		$21.9M Sell
158,355
-9,331
-6% -$1.11M 0.45% 66
2020
Q3 		$13.8M Sell
167,686
-6,513
-4% -$540K 0.33% 85
2020
Q2 		$13.6M Sell
174,199
-4,572
-3% -$303K 0.34% 85
2020
Q1 		$7.94M Sell
178,771
-33,616
-16% -$1.75M 0.24% 116
2019
Q4 		$9.07M Buy
212,387
+139,380
+191% +$5.75M 0.2% 137
2019
Q3 		$3.12M Buy
+73,007
New +$3.97M 0.07% 249

Other funds holding RARE

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Hussman Strategic Advisors
Hussman Strategic Advisors Ellicott City, Maryland $469M AUM 10.16% 1-Year Est. Return
Crestwood Advisors Group
Crestwood Advisors Group Boston, Massachusetts $6.76B AUM 24% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
Harbor Capital Advisors
Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Apollon Wealth Management
Apollon Wealth Management Mount Pleasant, South Carolina $8.72B AUM 23.07% 1-Year Est. Return
L. Roy Papp & Associates
L. Roy Papp & Associates Phoenix, Arizona $981M AUM 26.21% 1-Year Est. Return
Motley Fool Asset Management
Motley Fool Asset Management Alexandria, Virginia $2.64B AUM 26.58% 1-Year Est. Return

Pinnacle Associates's RARE Position: Q3 2026 in Review

Pinnacle Associates increased its Ultragenyx Pharmaceutical (RARE) stake by 17% in Q3 2026, buying an estimated $524K and bringing the position to 152,925 shares worth $2.3M. The position accounts for 0.03% of the portfolio, ranked #388.

Pinnacle Associates first reported a position in RARE in Q3 2019 and has held it in 29 quarters since. The position peaked at $21.9M in Q4 2020. 53 funds tracked by Wall St. Rank hold RARE as of Q3 2026.

  • Pinnacle Associates held 152,925 shares of Ultragenyx Pharmaceutical worth $2.3M as of Q3 2026.
  • Pinnacle Associates bought 21,821 Ultragenyx Pharmaceutical shares in Q3 2026, an estimated $524K.
  • Ultragenyx Pharmaceutical made up 0.03% of Pinnacle Associates's portfolio in Q3 2026, its #388 holding.
  • Pinnacle Associates first reported a position in Ultragenyx Pharmaceutical in Q3 2019 and has held it in 29 quarters since.
  • Pinnacle Associates's Ultragenyx Pharmaceutical position peaked at $21.9M in Q4 2020.
  • 53 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2026.

Based on Pinnacle Associates's 13F filing for Q3 2026, filed 20 Oct 2026.